Law ❯Regulatory Affairs ❯FDA Decisions ❯Drug Approval Process
The FDA has ruled that Eli Lilly's tirzepatide supply meets demand, requiring compounding pharmacies to phase out unbranded alternatives within 60 to 90 days.
